Ginkgo Bioworks Holdings vs Arcus Biosciences
Arcus Biosciences is the larger business, with $247m of revenue in fiscal 2025 against $170m for Ginkgo Bioworks Holdings (1.5 times as much). Arcus Biosciences grew faster (-4.3% against -25.1%). Arcus Biosciences kept more of each dollar of sales as profit: a net margin of -142.9% against -183.8%.
| Latest fiscal year | Ginkgo Bioworks HoldingsDNA, 2025 | Arcus BiosciencesRCUS, 2025 |
|---|---|---|
| Revenue | $170m | $247m |
| Revenue growth | -25.1% | -4.3% |
| Net income | −$313m | −$353m |
| Operating margin | — | -156.3% |
| Net margin | -183.8% | -142.9% |
| Return on equity | -51.1% | -63.3% |
| Free cash flow | −$179m | −$484m |
| Cash | $167m | $222m |
| Total debt | $0 | $100m |
| Debt to equity | — | 15.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 485 | 601 |
| Market value | $671m | $2.39bn |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 24 sales | 0 buys, 0 sales |